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TO OUR READERS
Appropriately , the MCV OUARTERL Y begins a new volume for 1 979 with a new format.
Although the basic alterations of size and mailing method were dictated by a desire to reduce
rising publication costs, we carri ed the impetus
to change even further with the introduction of a
new typeface and layout For example, the
table of contents will now be published on the
outside back cover for easy reference. These
and other modifications have streamlined ou r
appearance and provided a few more pages for
papers-papers which we hope will continue to
be of high interest to practicing physicians as
well as students of medicine .

INTRODUCTION
The McGuire Lecture Series honors Stuart
McGuire, M.D , L.LD . who served the Medical
College of Virginia from 1913 to 1948 as Professor of Surgery , Dean, President, and Chairman of th e Board of Visitors . His relentless dedication was a primary force in moving MCV into
the national mainstream of medical education.
Th e 50th McGuire Lecture Series presented current reviews in clinical cardiology and
hypertension for practicing physicians and medical students. Speakers were members of the
faculty of the Divisions of Cardiology and Cardiovascular Surgery at the Medical College of
Virginia, and Dean T. Mason , M.D ., Chief of the
Cardiovascular Section at the University of Californi a at Davis. Dr. Mason , who is the outstanding authority on the management of con-

gestive heart failure by reduction of the load
against which the heart must pu mp, was the
McGuire Lecturer.
Th e audience attend ing this lecture series
came from several states and represented various medical disciplines They entered freely into
the discussion and thus contributed greatly to
the value of the presentations We offer thanks
to them , to the lecturers whose talks are presented in thi s issue of the MCV OUARTERL Y, to
the Department of Continuing Medical Education whose planning for this symposium was
both thorough and efficient , and especially to
Dr. Mason , who gave a magnificent McG uire
Lecture .
DAVID W. RICHARDSON , M.D.
Chairman , Oivison o f Cardiology

The Role of the Exercise Stress
Test in the Adult
DONALD W. ROMHIL T , M D.
Fro m the Division of Cardiology, Medical College of Virginia , Health Sciences Division of Virginia
Commonwealth University , Richmond, Virginia

The use , limitations, and value of the exercise stress test have been under debate in the
recent cardiology literature . 1 - 5 The purpose of
th is discussion is to examine the current role of
the stress test.

Procedure
Common reasons for obtaining a stress
test are:
1 . Chest pain evaluation;
2. Screening for coronary heart disease
in asymptomatic persons;
3. Post-myocardial infarction , including
rehabilitation ;
4. Angina pectoris evaluation;
5. Arrhythmia evaluation--complementary to Holter monitoring ; this is less
sensitive than the 24-hour Holter monitor but will detect arrhythmias not
present on the Holter recording ;
6. Functional capacity evaluation (also
used in valvular heart disease and
other types of heart disease);
7. Evaluation of therapy (coronary bypass surgery, antiarrhythmic agents,
propranolol, rehabilitation programs).
Patients with the following problems are usually
not exercised :
1 . Recent myocardial infarction (although
the test can be done at three weeks to
a h'eart rate of 1 30 or symptoms , or at
two to three months to 85% of predicted maximal heart rate):
Correspondence and reprint requests to Dr . Donald
W. Romhilt , Box 51, Medical College ot Virginia , Richmond
VA 23298.
'

2. Acute myocarditis or pericarditis ;
3. Acute coronary insufficiency or unstable angina pectoris (since an exercise test can precipitate a myocardial
infarction , it is preferable to wait two to
three weeks until the patients 's condition is stable);
4. Rapid ventricular or atrial arrhythmias;
5. Second- or third-degree heart block;
6. Congestive heart failure ;
7. Acutely ill patients (infections, hyperthyroidism) ;
8. Severe symptomatic aortic stenosis.
For practical purposes, ST-segment
changes cannot be interpreted in the presence
of digitalis, left bundle-branch block , left ventricular hypertrophy with the ST-T wave
changes of the left ventricular stra'in pattern on
the resting ECG , or the Wolff-Parkinson-White
syndrome. The stress test is more difficult to interpret in patients with resting ST-T wave
changes , particularly in women . If possible , cardiac medications should be discontinued prior
to the test.
There are many different protocols for exercise tests. I prefer the submaximal graded
treadmill exercise test , using the Bruce protocol. 6 This is a continuous test with incremental
increases in the elevation and speed of the
treadmill every three minutes (Table 1 ). Patients
are exercised to a target heart rate which is
90% of their age-predicted maximum heart rate
(Table 2) The predicted maximum heart rate for
untrained individuals is 205 - .41 (age, years)
beats/minute and for athletically trained persons is 1 98 - .41 (age, years) 7 Post-myocardial infarction patients are exercised to 85%
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TABLE 1
Bruce Protocol
SPEED (mph)
1.7
2.5
3 .4
4 2
5 0
5.5
6 .0

STAGE
1
2
3
4
5
6
7

GRADE(%)

10
12
14
16
18
20
22

of their age-predicted maximum heart rate.
Thus , the stress test requires a considerable
amount of effort on the part of the patient.
The major reasons for stopping an exercise test are as follows:
1. Target heart rate ach ieved;
2. Chest pain typical of angina pectoris;
3. Arrhythmias such as
a. prem ature ventricu lar contraction s-pairs , bigeminy , R on
T , or increasing frequency ,
b . v e ntricular tachycardia (~3
PVCs) ,
c. atrial fibrillation , flutter , tachycardia ,
d. heart block-second- or third-degree ;
4. Marked hypertension (>250 mm Hg
systolic) ;
5. Hypoten sion with continuing exercise
(>1 0 mm Hg fa ll in systolic pressure) ;
6. Fatigue , weakness , dyspnea;
7. Cerebral symptoms such as dizziness ;
8. Intermittent claudication ;
9 . Decrease in heart rate with continuing exercise ;
1 0 . Marked ST-segment depression;
11 . General appearance-pale , vasoconstricted appearance .

Interpretation
The interpretation of the exercise test is
based on ST-segment changes , although there
are other factors to be considered. The exercise
test is considered positive when there is 1 mm
of add iti onal ST-segment depression which is
horizontal or down-sloping for at least .08 seconds (Fig 1) or 1 mm of ST-segment elevation in
an ECG lead without 0 waves. When ST-segment elevation occurs with exercise in a lead
without O waves, there is usually a very critical
narrowing of at least one of the coronary arteries. The following are other findings which
should be considered in the interpretation of the
exercise test:
1 . Chest pain typical of angina pectoris
during the test should be recorded in
the interpretation .
2. An increase in R wave height with exercise in the left precordial leads is abnormal. 8 Patients without corona ry
heart disease decrease their systo lic
and diastol ic vo lum e progressively
with exerc ise wh ich results in a decrease in R wave height ; the ischemic
ventricle is unable to decrease its volume and R wave height increases.
3. Inverted U waves in the absence of
antiarrhythmic drugs or left ventricular
hypertrophy ; in c id ence is probably
small.
4 . Hypotensive response to exerc ise: A
fall in systo li c blood pressure of 1 0
mm Hg or more is abnormal ; other
etiologies of severe heart disease and
vasovaga l responses must be excluded.
5. Ventricular arrhythm ias: Premature
ventricular contractions at low heart
rates (below 1 30) with exercise in patients who do not have PVCs at rest;

TABLE 2
Maximal Heart Rates (MHR)
20

25

30

35

MHR
9 0 % MHR
85% MH R

197
177
167

195
175
166

193
173
1 64

19 1
172
162

AGE (yea rs)
40
45
50
PHYSICALLY TRAINED
18 7
184
189
170
168
166
160
156
161

MHR
9 0 % MHR
85% MHR

190
171
161

188
169
160

186
167
158

184
166
156
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55

60

65

70

75

182
164
155

180
162
153

178
160
151

176
158
150

174
157
148

17 2
155
146

PH YSICALLY UNTRAINED
182
18 0
177
17 5
164
162
159
158
155
153
15 0
149

173
156
147

171
154
145

169
152
144

167
150
14 2

165
149
140
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these are probably not specific for coronary heart disease .
6. Development of a pansystolic murmur
of mitral regurgitation .
The interpretation of the exe rci se test
must be assessed in the clinical setting in which
it occurs. The largest amount of information is
available in patients with chest pain. A few
years ago we evaluated the sensitivity and
specific ity of the exercise test in 1 24 patients
with chest pain undergoing coronary arteriog raphy. 9 The criterion for a positive exercise
test was 1 mm of additional ST-segment depression (or elevation) which was horizontal or
down-sloping for . 08 second. Sixty-five patients
had greater than a 50% narrowing of one coronary artery; 49 (75%) of these had a positive
exercise test ; thus there were 25% false-negatives . Fifty-nine patients had less than a 50%
narrowing in any coronary artery; 4 (7%) had a
positive exercise test and were considered to be
false-positives. This sensitivity of 7 5% and

specificity of 93% is comparable to eight other
studies 10 - 11 where sensitivity ranged from 54%
to 80% and specificity from 88% to 97% . The
sensitivity of the exercise test will be higher in
patients with three-vessel disease than in patients with single-vessel disease. The use of
slowly up-sloping ST seg men ts with ST-segment
depression greater than or equal to 1 .5 mm at
80 msec after the J point increased the sensitivity in one study from 64% to 76% but decreased specificity from 93% to 82%. 17 It is important to reali ze that most false-negative
calculations include only those patients who
reach their target heart rate .
In general , patients with more severe coronary artery disease will have an exercise test
which is positive at lower heart rates and during.
the early stages of the test . We compared the
maximum heart rate achieved during an exercise test with the severity of coronary artery disease on angiography 18 in 40 patients with a
positive exercise test. 8 There was a significant
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Fig 1-Example ot positive exercise test. In the exercise tracing there is more th an 1 mm ot ST-segment depression which is
horizontal and persists tor more than .08 seconds.
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inverse correlation (p >.001, r = -0.62) between the severity of coronary artery disease
and the maximum heart rate achieved (Fig 2). In
a recent study patients who had a positive exercise test in stage I or II had : (1) greater than a
60% chance of having three-vessel disease , (2)
greater than a 25% chance of having main left
coronary artery disease, (3) greater than a 97%
chance of having coronary heart disease, and
(4) nonsurgical patients had a survival rate of
85% at one year and 63% at four years. 19
In post-myocardial infarction patients the
diagnosis of coronary artery disease is established , but the exercise test may provide useful
information . A recent study has shown that an
exercise test to symptoms, or a heart rate of
130, is safe at three weeks post-infarction. 2 0
Patients with a positive test based on ST-segment depression have a significantly higher
incidence of cardiac events during the next
eighteen months. At two or three months postinfarction patients who have additional ST-segment elevation in leads with a 0 wave have a
high incidence of either a ventricular aneurysm
14
13
12
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In summary, the exercise stress test
provide useful information in the diagnosis
prognosis of patients with heart disease or
pected heart disease when it is interpreted
the knowledg e of the clinical findings.
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or a large infarction. 2122 Post-infarction patients22 with a positive exercise test based on
ST-segment depression are likely to have multiple-vessel disease (8 7%) compared to patients
with a negative test who are likely to have
single-vessel disease (62%).
The assessment of the meaning of a positive exercise test is most difficult in the asymptomatic patient . It is difficult to determine the sensitivity and specificity in this population because
coronary arteriograms are not routinely done . In
selected populations where th ey have been
done the incidence of false-positives has
ranged from 36% to 69% 23 - 25 and were lowest
in the least selected population . The persistence of ST-segment depression for two minutes after termination of exercise may improve
the specificity in asymptomatic patients. 26 Despite the large percentage of false-positives ,
there is a significant increase in cardiac event
rate (myocardial infarction and sudden death) in
asymptomatic subjects with a positive test compared to those with a negative test. 21 Also, it
should be recogni zed that the significance of a
positive exercise test is entirely different in an
asymptomatic young woman who has 1 mm of
horizontal ST-segment depression at the end of
the tenth minute of exercise which lasts for 20
or 30 seconds compared to a middle-aged man
with 2 or 3 mm of horizontal ST-segment depression in the fourth minute of exercise which
persists for several minutes.
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Thallium 201 Myocardial Imaging
MICHAEL J. COWLEY, M.D.
Assistant Professor of Medicine, Cardiovascular Disease, Medical College of Virginia, Health Sciences
Division of Virginia Commonwealth University, Richmond, Virginia

In recent years technological advancements in nuclear medicine have resulted in increasing interest in the use of radioisotope techniques in the evaluation of card iac disease , and
cardiovascular nuclear medicine has developed
into a useful noninvasive tool in clinical cardiology. Myocardial infarct imag ing with technetium-99m pyrophosphate has been demonstrated to be a reliable method in the diagnosis
of suspected myocardial infarction . 1 2 Radioisotope card iac flow studies are useful in the diagnosis and follow-up of congen ital heart disease ;3 and gated cardiac blood pool imaging is
emerging as an important technique in the evaluation of left vent ri cu lar function and ejection
fraction. 4 5 One of the more promising recent
appli cations of nuclear medicine in cardiology
has been the development of myocardial perfusion imaging in the evaluation of coronary artery disease. Thallium 201 is the major radioisotope emp lo yed in myocardial perfusion
imaging and this report will review its basic
properties and its use in the diagnosis of ischemic heart disease.

Myocardial Perfusion Imaging
Myocardial perfusion imag ing (MPI) refers
to the use of certain radioisotope tracers which
are rapidl y and selectively concentrated in the
heart . It is based on the principle that myocardial uptake of these isotopes occurs primarily as a function of myocardial blood flow and
function . The resultant pattern of activity provides an assessment of regional myocardial
blood flow by comparing the amount and distriCorrespondence and reprint requests to Dr. Michael

J Cowley, Box 95, Medical College of Virginia, Richmond,
VA 23298.
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bution of activity in different areas of the heart .
Regions of normal and abnormal myocardium
are thereby distinguished by the presence and
location of differences in myocardial radioactivity. Of the various radioisotopes which
have been used for MPI , thallium 201 possesses the best radiation characteristics (Table
1) and has been the most widely investigated.
Thallium 201 is an analogue of potassium and
exhibits similar biologic and physical properties6; it is a monovalent cation with a half-life of
73 hours and is readily concentrated in the
myocardium by an active transport process
involving membrane sodium-potassium
adenosinetriphosphatase (ATPase). Thallium
201 emits low-energy photons which permit
imaging with a scintillation camera and provide
for high spatial resolution ; it has a high myocardial extraction ratio , with 80% to 90% of an
injected dose concentrated in the heart within
the first few minutes , and exhibits a high myocardial-to-background ratio which contributes to
improved image resolution. These features allow for prompt imaging following injection and a
low patient radiation dose .
Myocard ial activity with MPI is dependent
on both the initial distribution of the radioisotope
and its subsequent redistribution with time. The
distribution phase is most important with early
imaging and is determined both by isotope delivery to different regions of the heart and by
myocardial extraction. Radioisotope delivery is
a flow-dependent process and has been shown
experimentally to be proportional to regional
myocardial blood flow. 7 Myocardial extraction
of thallium 201 is a cell-dependent process requiring functioning myocardial cells. Distribution
of thallium 201 occurs rapidly into normal areas

of myocardium but may be significantly delayed
to zones of diminished coronary blood flow and
may be absent in regions of abnormal function
which are unable to concentrate the isotope.
Redistribution is homogeneous in normal hearts
but is heterogeneous in zones of significantly diminished flow or function. Washout of thallium
2 01 begins early from normal areas and is detectable at one hour; while this is in process
from normal areas, continuing uptake is often
occurring into flow-limited areas which exhibit
initially delayed myocardial uptake. These regions will eventually show normalization of activity if viable myocardium is present , and redistribution is usually complete within one to four
hours. 8 Areas of persistently diminished activity
generally indicate impaired myocardial function
and represent myocardial infarction.

Technique
Thallium 201 in a dose of 1 to 2 mCi is
administered intravenously either at rest or at
the peak of exercise when MPI is used in conjunction with treadmill exercise testing . Myocardial images are recorded using a stationary
or portable scintillation camera. Early images
are obtained 1 0 to 1 5 minutes after injection
and reflect the status of myocardial perfusion at
the time of injection. If the early image is abnormal , delayed imaging three to four hours later is
performed to look for redistribution into ischemic areas. Multiple views are obtained to assess the different areas of myocardium with
minimal superimposition and overlap. Interpretation is done by comparison of regional
myocardial activity; a normal image will demonstrate a relatively homogeneous distribution of
radioisotope within the left ventricle (Figs 1 and
2), and an abnormality is represented by diminished activity, appearing as a "cold" .area (Fig
3) A defect which is persistent on late images
indicates damaged myocardium or scar (Fig 4),
and a transient defect which is present on early
images but has resolved with delayed imaging
represents an area of reversible ischemia (Fig
5). Difficulty with interpretation may occur when
only small differences in regional activity are
present, but this may be improved by use of
computer processing techniques.
Myocardial Infarction
One area of clinical application of thallium
201 MPI is in the diagnosis of myocardial in-
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Fig 1- No rmal thallium 2 01 MPI in the anterior (ANT), left
an terior oblique (LAO), and left lateral (LLA TL) projections
Myocardial uptake in the left ventric le is intense and homogeneous. The diagram to the right of each image indicates
the ventric ular and coronary anatomy in each projection.
AW = anterior wall ; FW = free wall ; IVS = interventric ular
septum ; IW = left ventric ular inferior wall; LAD = left anterior descending artery distribution; LC = region of left c irc umflex arte ry ; PLW = posterior lateral wall ; RCA = right
coronary artery distributio n.

farction. Several investigators have demonstrated a high sensitivity for thallium 201 in the
detection of acute myocardial infarction. 9 - 1 1 In
these studies sensitivity was greater than 95%
in patients with transmural infarction and from
80% to 85% for nontransmural infarction. Sensitivity is unaffected by location of infarction but
is dependent on infarct size, with decreased
TABLE 1
Myocardial Perfusion Imaging
Radio nuc lides K-4 3 , Rb-81 , Cs-1 29, Tl-20 1
• Analogues of K + : physical and biologic
·Tl-2 0 1 - best radiation c haracteristics
• tYi - 73 hours
• low-energy emission c haracteristics
• hig h myocardial extraction ratio (8 0 % )
• high myocardial-to-background ratio
• low patient radiatio n dose (07 rad / mCi)
• usual dose = 1 to 2 m Ci
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GXT

c
Fig 2 -Normal thallium 201 study with exercise (GXT) in the anterior (left), left anterior oblique (center) , and left lateral ( righ t)
views. Activity in the left ventricle is homogeneous and intense, and there is activity seen in the right ventricle in the left and
center panels. Right ventricular activity is often detectable with exercise. This patient had typical angina pectoris with normal
coronary arteries on angiography and a false-positive exercise electrocardiogram.
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MYOCARDIAL SCINTIGRAMS
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Fig 3-Abnormal thallium 20 1 rest image in the anterior (ANT), left anterior oblique (LAO), and left lateral (LL) pro1ections in a
patient with acute anterior myocardial infarction . A large area of diminished activity is evident in the anterior and apical regions
of the left ventricle in each projection.
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Fig 4-Thallium 201 exercise MPI with early (left) and delayed (right) images in the left anterior oblique projection in a patient
with atypical chest pain and history of previous myocardial infarction. The immediate image shows an anteroseptal defect and
the delayed image recorded four hours later shows no redistribution into this area, indicating a fixed or irreversible defect from
previous myocardial infarction.

Fig 5-Thallium 201 exercise (GXT) study in a patient with angina pectoris. The image at left was recorded immediately following com pletion of exercise and demonstrates a large area of markedly diminished activity in the anteroseptal region of the left
ventricle. The image at right was obtained four hours later and shows redistribution of activity into the anteroseptal reg ion with
normalization of activity, indicating reversible, exercised-induced ischemia.
COWLEY
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leaving only the residual area of infarction apparent on su bsequent images. The size of the
defect with thallium 201 MPI also correlates
well with the size of the infarct as determined by
serum enzyme techniques, 1 2 pathological analysis, 11 and quantitative left ventricular angiography . 13 However, application of thallium 201 MPI
in suspected myocardial infarction is limited in
patients with previous myocardial infarction because of the isotope 's inability to distinguish
new infarction from old infarctions or ventricular
aneurysm . There is also reduced specificity with
small infarctions (as with serum enzymes and
electrocardiographic diagnosis) because of the
limits of resolution of the technique . 14 In addition , MPI at rest may be abnormal with early
imaging in some patients having unstable an-

LAO

LLAT L

Fig 6-Serial thallium 201 MPI in anterior (ANT), left anterior oblique (LAO), and left lateral (LL) projections in a patient with posterior wall infarction. Arrows indicate a defect
at 4.5 hours after onset of chest pain This defect is diminished on the repeated studies 24 hours and 8 days later,
especially in the LAO view.

sensitivity in small infarctions . Sensitivity is also
dependent upon time, with rare false-negative
studies being obtained in the first 6 hours after
infarction and an increased incidence of falsenegative results observed after 24 hours. 9 In addition , serial thallium 20 1 studies in the same
patient have also demonstrated that the size of
the defect often changes with time, usually
being largest during the first 24 hours and becoming smaller and more stable in size after 48
hours (Fig 6).9 This observation probably indicates detection of zones of reversible peri-infarction ischemia in addition to acute infarction
in its early course which resolves with time ,
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TABLE 2
Exercise Thallium Imaging
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Fig ?-False-negative stress electrocardiogram. Resting
CLINICAL APPLICATIONS

Improved sensitivity over exercise testing alone
Clarification of equivocal stress test
Diagnosis when stress test uninterpretable
Conduction defect (LBBB)
Left ventricular hypertrophy
Resting ST-segment abnormality
Digitalis effect
Identification of false-positive stress test
Evaluation of coronary bypass graft function
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(top) and stress (bottom) electrocardiogram and thallium

201 MPI in the anterior (ANT), left anterior oblique (LAO),
and left lateral (LLATL) projections in a patient whose coronary angiograms (SCA) demonstrated significant left anterior descending coronary artery stenosis. The resting scintigram reveals homogeneous radioactivity. With stress, the
interventric ular septum and anterior left ventricular walls (arrows), the regions supplied by the stenotic vessel, are
barely visable. The electrocardiogram shows no ischemic
change on exercise.
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Fig 8-Normal thallium 201 MPI and equivocal stress electrocardiogram in a patient with normal coronary arteries on
ang iography (SCA) Resting (top) and stress (bottom) electroca rdiogram and stress imag ing in the anterior (left) , left
anteri or oblique (center) and left lateral ( right) projections in
a patient with troublesome atypical chest pain and a history
of hypertension. Th e fu ll resting electrocardi ogram revea led
left ventric ul ar hypertrophy (L VH) Th e monitored lead
showed ST-segment depression that deepened with stress
and was difficu lt to interpret in view of the depression at
rest. The perfusion image was norma l and clari fied the
stress electrocardiog ram
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Fig 9-Fa lse-positive stress elect rocard iog ram. Stress thallium 20 1 MPI in the anterior (ANT), left an terior oblique
(LAO) , and left lateral (LLA TL) pro1ect1ons (top) and the resting and stress electrocardiog rams (bottom) in a pa tient with
normal corona ry art eri es on angiography (SCA), Rad ionuc lid e dist ributi on was norma l , but the st re ss electrocardiogram showed distinct and sign ificant horizontal STsegment depression Scint1graphy proved to be the valid
clinical indicator.
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gina witho'ut infarction owing to severely reduced flow , 1 5 but this can usually be clarified if
delayed images are also obtained. Thallium
201 studies may also be abnormal in certain
forms of noncoronary heart disease, particularly
cardiomyopathy . 16 For these reasons , thallium
201 MPI appears to have limited general usefulness for the diagnosis of acute infarction but
can be of value to confirm infarction in situations when standard criteria are not helpful. It
has been useful in screening patients for coronary care unit admission. 9

Exercise Myocardial Imaging
Thallium 201 MPI has its greatest application when used in combination with treadmill
exercise testing for the evaluation of chest pain
and tran sient myocardial ischemia , 1 7 - 2 0 and it
provides advantages over exercise testing alone
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Fig 1 0-Preoperative (top) and post-operative (bottom)
th alliu m 20 1 MPI 1n th e 45-degree left anterior oblique
(LAO) projection in a patient who underwent coronary bypass surgery Th e preoperative rest image (top, left) is normal, but following exercise (ETT) th ere is an extensive defect in the anteroseptal region (top right) preoperatively.
Postoperatively both rest (bottom, left) and exercise (bottom, right) are normal . The bypass graft was patent on angiography.
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(Table 2). Thallium 201 is administered at the
peak of exercise, and early images are obtained. If a normal image is recorded , further
imaging is unnecessary (Fig 2). If an abnormality is present, delayed images are recorded to
assess the redistribution into ischemic areas
(Fig 5). When compared with standard exercise
electrocardiography, thallium 201 MPI is significantly more sensitive than exercise testing in
the detection of coronary artery disease. This
improved sensitivity is present in patients with a
normal resting electrocardiogram (ECG) in
whom exercise testing is most reliable (Fig 7),
and is found particularly in patients with an abnormal resting ECG, in whom ECG changes
with exercise are often difficult to interpret or are
uninterpretable. This is encountered in patients
with intraventricular conduction defects, particularly left bundle-branch block ; left ventricular hypertrophy (Fig 8); nonspecific resting ST-segment abnormalities ; and in patients tak ing
digitalis or other medications which may alter
the resting and exercise ECG.
Thallium 201 also has a higher specificity
in detection of coronary artery disease than
standard treadmill exercise testing , as falsepositive results with thallium 201 are infrequent
(Fig 9). 11 · 1 9 In contrast, the incidence of falsepositive results with exercise electrocard iography may be as high as 30% in certain patient populations 21 Th allium 2 01 exercise imaging is complementary to exercise testing , and
diagnostic accuracy is improved when they are
used in combination. In several series, this accuracy exceeds 90% in the detection of significant coronary artery disease. ' 7 · 19
MPI with thallium 201 may also be of
value in the postoperative evaluation of patients
having coronary artery bypass graft surgery, as
changes in regional myocardial perfusion with
MPI have been shown to correlate well with bypass graft function, 22 thereby providing a noninvasive method of determining graft patency or
closure (Fig 1 0).
In summary , MPI with thallium 2 01 is a
new and effective noninvasive technique in the
diagnosis of ischemic heart disease. It can reliably detect myocardial infarction and may be
useful when the diagnosis of acute infarction by
other means is uncertain. Exercise thallium 201
imaging is the area of greatest clinical application of MPI , resulting in improved sensitivity
14 /
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and specificity over exercise testing alone, and
in high diagnostic accuracy in the detection of
coronary artery disease when used in combination with exercise electrocardiography. Thallium
20 1 MPI is also of value in the evaluation of coronary artery bypass graft function.
Figures 1, 7, 8, and 9 are reproduced with permission
from the American Journal of Cardiology (41 :43-51,
1978)
Figure 6 is reproduced by permission from the New
England Journal of Medicine (295 1-5, 1976)
Figure 1 0 is reproduced from Circulation (56 830836, 1977) by permission of the American Heart Association, Inc.
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Indications for Cardiac Catheterization in the
Diagnosis and Management of Coronary
Artery Disease
GEORGE W VETROVEC, M.D.
Assistant Professor of Medicine and Cardiology, and Director, Cardiac Catheterization Laboratory,
Medical College of Virginia , Richmond, Virginia

In 1979 coronary ang iography remains
the standard test for diagnosing the presence
and extent of coronary artery disease. Noninvasive studies such as exercise testing are
only relative predictors of coronary anatomy.
Therefore, to define spec ifical ly whether or not
coronary disease ex ists in a given patient and, if
present , to delineate its location , severity and
the potential for bypass surgery , a coronary
angiogram is th e test to obtain . Th e purpose of
this paper is to disc uss indicati ons for coronary
angiography in the management of patients
with established or suspected coronary disease .
Figure 1 shows a schematic representation of the normal cardiac blood supply The left
and right coronaries exit directly from the aorta ,
and the left main coronary divides into two major branches , the left anterior descending and
the circumflex vessels. It is important to note the
extensive blood supply to the heart-mainly the
left ventricle-through the left main coronary
and its branches. Therefore , the left main coronary is frequently considered in a special class
wh en discussing coronary artery disease. Other
important vessels include th e left anterior descending, the circumflex and the right coronary
arteries . The term "s ingle- ", " double- ," or
''triple-vessel disease '' refers to the number of
these three important vessels involved with significant disease. Obstructive lesions of the coroCorrespondence and reprint req uests to Dr . George
W Vetrovec, Box 36, Medical College of Virginia, Rich mond, VA 23298 .
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naries represent the bui ld-up of atherosc lerotic
material which decreases the vessel lumen and
thereby decreases blood flow through the vessel. During coronary ang iog raphy, rad iopaque
dye is injected selectively into each coronary artery to all ow visualization of each vessel and its
majo r branches.
Figure 2 illustrates a sing le-frame cine
from such a procedure ; the sign ificant atherosclerotic lesion is clearly demarcated. Therefore , using this techn ique, the extent and location of coronary artery lesions can be
specifica ll y identified.
Table 1 lists seven indications for coronary ang iography. Considerab le controversy
continues to exist about the overall benefits of
coronary bypass surgery and therefore it is extremely difficult to be unequivocal in li sting
one's indi cations for coronary ang iography.
However, the general gu idelines given here are
thought to be the most reasonable , although
clini cal circumstances must be carefu ll y analyzed for each patient prior to proceeding to
coronary ang iography.

Symptomatic Indications
The first and probably most frequent indication for coronary ang iography is failure of a
patient to respond to reasonable medical management; the term " reasonable medical management'' is used because of the wide response of patients to medical treatment . Some
patients ' response is less than ideal because of
poor drug comp li ance while others have intoler-

able side effects to the medications such as severe protracted headaches associated with nitrate administration , or significant fatigue or bad
dreams associated with propranolol. In addition,
a prior history of asthma or congestive heart failure is a contraindication for the use of propranolol. Finally , despite adequate medical
management, some patients remain incapacitated because of their chest pain In any situation in which a patient fails to get adequate
symptomatic benefit from medical treatment
and/or has significant side effects associated
with the treatment , coronary angiography
should be considered to determine if he or she
is a candidate for coronary bypass surgery
Clearly 80% to 90% of patients have a significant reduction in symptoms and medication requirements following coronary bypass surgery
and many of them remain symptom-free . 1 In a
study of 1 00 patients randomly assigned to
medical or surgical treatment , Mathur and
Guinn 2 documented significantly improved
treadmill performance for post-bypass surgery
patients when compared with their medically
treated counterparts. Furthermore, subsequent
to treadmill testing , 70% of the surgical patients
had no angina while only 20% of the medical

Fig 2 -Left main coronary obstruction. Th e left coronary
system seen in a late ral projection is fi lled with contrast medium duri ng a contrast injection Note critica l left main artery
stenosis ( arrol'Yj

group were angina-free Th ese data emphasize
the symptomat ic benefits of coronary bypass
surgery
In addi ti on to symptomatic benefits of coronary bypass su rg ery, certain subgroups of pati en ts have improved longevity following this
procedure . Ongoing studies will continue to better delineate th ese subgroups , but at present
those patients with left main coronary artery disease appear to show improved function and
prognosis as a resu It of the bypass operation .
Thi s fact is well illu strated by a three-year followup of the subgroup of patients with significant
left main artery disease from th e VA Cooperative Study 3 In thi s stud y, 1 2 (29%) of 41 medically treated patients died in the three-year follow-up compared to only 3 (7%) of 4 2 patients
in the su rgi ca lly treated group; the difference
was significant (p ~ 0 .01 ). In addition , the ben-

1.
Fig 1-Sc hematic coronary ana tomy Th e right and left coronary arteries ari se from th e aorta. Th e short main left (LC)
artery bifurcates in to two large branches, th e left anterior
descend ing (LAD) artery and th e circumflex (CX) artery supplying most of th e anterior and lateral myocardial surface.
Th e ri ght coronary (RC) artery supplies th e in ferior myocardium through th e posterior descending (PD) artery.

2.
3.
4.
5.
6.
7.

TABLE
Indications for Coronary Angiography
Angin a inadeq uately responsive to reasonable medica l
management
Un stable angina
Atypica l ang ina
" High-Ri sk" co ronary patients
Undiag nosed chest pa in
Heart fa ilure post-myocard ial infarction
Recurrent ang ina post-coronary bypass surgery
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efit appeared to be greatest in those patients
with associated right coronary disease.
Therefore, patients who do not respond
well to reasonable medical treatment, and who
are surgical candidates have an excellent prospect for improved functional status following bypass surgery. Furthermore, patients with left
main vessel disease and perhaps yet-to-beproven other subgroups have improved longevity following the bypass operation.

Unstable Angina Pectoris
A second major consideration for coronary angiography is patients who have unstable
or rapidly worsening angina pectoris; in certain
instances, these patients may even be classified
as having pre-infaction angina . Most cardiologists feel that such patients should be stabilized
first, if possible, with vigorous medical treatment. This philosophy is supported by studies
suggesting that the risk of emergency coronary
angiography and bypass surgery to patients
with unstable angina is equal to the risk of initial
medical management as far as morbidity and
mortality are concerned 4 ; however, patients
who do not respond to medical treatment are
candidates for angiography and coronary bypass surgery to relieve their persistent symptoms. For those patients who do respond to
medical treatment the question then arises as to
whether they should be catheterized and, if so,
when. Generally, it seems prudent to consider
angiography for young, active patients with unstable angina even though they respond to
medical treatment, as a review of the angiographic and historical data will show.
Coronary angiography on large groups of
patients who have had recent unstable angina
have shown a 1 0% to 1 5% incidence of left
main coronary disease. 4 5 This finding is important because these patients have improved survival following bypass surgery . In addition, from
5% to 20% of patients may show normal coronary angiograms; variability of this number relates to the criteria used in any given study for
the diagnosis of unstable angina. When accompanying electrocardiographic changes are required for the diagnosis of unstable angina, the
incidence of normal coronaries associated with
this chest pain syndrome is reduced . However,
identifying normal coronaries is important as
many patients are then found to have a noncardiac cause for their chest pain. Rarely, indi-
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viduals may have angina with normal coronaries, but generally these patients do well, with
infrequent symptoms and a much lower risk of
myocardial infarction than those patients with
obstructive coronary disease. Therefore, the diagnosis of normal coronaries allows one to be
much more positive in reassuring the patient
about long-term survival. In addition to these
subgroups, a majority of the remaining patients
with unstable angina have significant three-vessel disease, a group that many feel may benefit
from bypass surgery in terms of symptoms and
prognosis.
One third or more of non-surgical patients
who have unstable angina will have a subsequent unstable period within six months despite medical treatment. 5 Excluding left main
vessel disease, in randomized studies comparing medical versus surgical treatment for unstable angina, there was no significant difference in morbidity (subsequent myocardial
infarctions) and mortality when the two groups
were compared after four months or after 1 %
years. 6 However, these studies emphasize the
improved functional performance seen in those
patients who undergo surgery. Considering the
higher incidence of left main vessel disease, the
moderately frequent occurrence of normal coronaries and the significant subsequent disability
of medically treated patients, coronary angiography is warranted in active individuals with unstable angina to better define the programs and
appropriate treatment plan.

Atypical Angina Pectoris
A third consideration for coronary angiography is in those patients who demonstrate
atypical or Prinzmetal type angina pectoris. This
syndrome is charactreized by chest pain at rest
with associated significant ST-segment elevations which are transient in nature. These patients are often subject to significant rhythm disturbances and/or conduction abnormalities
with the chest pain episodes. 7 Anatomically, patients with atypical angina may have either highgrade fixed obstructive lesions or normal coronaries with intermittent vessel spasm producing
the symptoms . These patients are frequently
difficult to manage medically, thus the distinction between significant obstructive disease
and spasm is important from the standpoint of
therapeutic options, as patients with significant
obstructive disease generally benefit from by-

pass surgery whereas patients with spasm do
not .

High-Risk Patients
Symptoms of angina do not correlate well
with the extent of disease. Ideally , one would
like to have a simple noninvasive test that would
identify those patients who have significant left
main vessel disease which derives so much
prognositc benefit from bypass surgery, but no
such test is available. However, certain exercise
test responses are considered suggestive of severe coronary artery disease which frequently
includes left main vessel disease. Table 2 lists
those high-risk abnormalities. Included in this
group 8 are patients who develop marked (2 mm
or greater) ST-segment depression with exercise testing , particularly at low levels of exercise
performance. In addition , the development of
ST-segment elevation on treadmill testing in an
area of the electrocardiogram not showing a
prior myocardial infarction is a significant predictor of severe proximal coronary disease if not
of left main vessel disease. 9 Finally , patients
who develop hypotension at nonmaximal exercise performance are again likely to have significant disease. 10 Such hypotension suggests severe myocardial ischemia consistent with
marked proximal coronary artery disease . In
these high-risk patients coronary angiography is
important to delineate this anatomic abnormality.
Other high-risk patients include those who
have a history of prior myocardial infarction and
significant symptomatology and / or poor exercise test responses , particularly if they are in the
high-risk category listed above. Furthermore ,
subendocardial myocardial infarctions may represent another significant risk group . Fifty consecutive patients with a recent condition of this
type at the Mayo Clinic 1 1 showed a high frequency of symptomatic disability in a short-term
ten-month follow-up. Fifteen patients (30%) had
significant stable angina pectoris and nearly
half , 23 (46%) of 50 , developed unstable angina
over the short time of the study ; only 1 2 (24%)
of the 50 remained angina-free. Considering
the frequency of significantly limiting symptomatology in this study, early angiography in patients with a recent subendocardial myocardial
infarction seems warranted to identify those patients who are candidates for bypass surgery,
particularly in physically active individuals.

TABLE 2
Exercise Test Predictors of Potentially Severe
Coronary Disease
1 . Marked ST-segment depressio n
2. ST-segment eleva ti on in an area of noninfarcti on of
th e ECG
3. Hypotension at nonmax imal performa nce

Chest Pain Diagnosis
To this point , the discussion has centered
on the diagnosis of the extent of coronary disease. Another consideration for coronary angiography is specifically to exclude the existence
of coronary disease. Not every patient with
vague, intermittent or poorly defined chest discomfort is a candidate for a coronary angiogram ; however, there are those in whom noninvasive studies , including exercise testing and
perhaps thallium imaging , fail to demonstrate
clearly whether or not coronary artery disease
exists. Most of these patients have symptom
complexes with components that are both typical and atypical of angina . In addition , the concern about the possibility of coronary disease
may be limiting these patients ' lifestyles . In such
instances , coronary angiography is warranted
to provide a definitive diagnosis.
Congestive Heart Failure
Congestive heart failure after a myocardial
infarction can be a difficult management prob~
lem , particularly if it does not respond to routine
medical treatment for heart failure. Left heart
failure may be manifested either as a congested
state with recurrent pulmonary edema and
shortness of breath or as a low-output state in
which the patient's major complaints relate to
low forward cardiac output, that is, fatigue,
weakness and exercise intolerance without
chest pain. Clinical findings frequently include
either a mitral regurgitation murmur, ventricular
gallop rhythms and / or a contour on apex palpation , suggesting a left ventricular aneurysm .
Anatomically , one wishes to know whether or
not there is a localized aneurysm or significant
mitral regurgitation . Cardiac catheterization of
patients who fail to respond to routine treatment
will delineate the severity and location of left
ventricular wall motion abnormalities as well as
whether or not there is significant valvular insufficiency. In addition , coronary angiograms
identify obstructive vessels which may exist in
the areas of remaining functional myocardium.
VETROVEC
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Patients with severe diffuse non-localized left
ventricular dysfunction are generally not candidates for bypass surgery , because in such instances the operative risk is increased and
there is no benefit in terms of reducing heart
failure. However, if a localized , correctable mechanical problem exists such as a left ventricular aneurysm or significant mitral regurgitation,
the condition of these patients may be significantly improved by surgical correction of the
appropriate defect with or without additional bypass surgery as dictated by the coronary anatomy.

Recurrent Angina Pectoris Post-Bypass
Surgery
Finally , those patients who have previously undergone bypass surgery and who developed recurrent angina pectoris may need angiography; as the frequency of bypass surgery
increases, so will the numbers of such patients.
Two factors determine the need for repeat coronary post-bypass angiography. First, if the recurrent angina occurs within one to two months
following bypass surgery, it is likely that one or
more vein bypass grafts have occluded. 12 In this
event the preoperative angiograms should be
reviewed and the anatomy discussed with the
surgeon. If the distal vessels suggest poor distal
runoff either angiographically and / or at the time
of surgery and the post-bypass flows were poor,·
it is unlikely that reoperation will carry any better
chance of maintaining a patent graft, and consideration of repeat catheterization should be
postponed unless medical treatment fails to be
effective. Conversely , if flows were good at the
time of surgery and the distal runoff appeared
adequate, graft failure might be caused by a
technical problem resulting from surgery Reoperation could conceivably benefit such a patient, thus a repeat angiogram is warranted ;
however, early recurrent angina is most often
seen in patients with severe distal disease.
A further consideration for angiography is
the patient who has experienced marked symptomatic improvement for a long time following
the bypass operation. When recurrent angina
occurs in such a patient , the anatomic problem
is generally not in the graft but represents progression of the disease in the native circulation,
either distal to the graft insertion or in other nongraftable vessels . Depending on the symptomatology and the state of the other vessels at the
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time of surgery , it is reasonable to consider a repeat study in these patients , looking for other
potentially graftable vessels.
The foregoing discussion should provide a
reasonable approach to the utilization of cardiac
catheterization and coronary angiographic techniques in the diagnosis and management of patients with coronary artery disease. Combining
the functional performance information derived
from noninvasive tests with the anatomic abnormalities demonstrated with coronary ang iography provides the most thorough evaluation of
patients with coronary disease. The information
derived from coronary angiography is frequently
important in the prognostic and therapeutic decisions regarding patients with coronary disease.
Figures 1 and 2 are reproduced with permission from
B Soto, RO Russell , RE Morask1 Radiogra phic A na tom y of
the Coronary A rteries: An Atlas. Mount Kisco (New York),
Futura Publishing Company , Inc , 1976.
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Afterload Reduction Therapy for Congestive
Heart Failure
DEAN T. MASON , M.D .
From the Section of Cardiovascular Medicine, Departments of Medic ine and Physiology, University of
California , School of Medicine , Davis , Ca liforn ia , and Sacramento Medical Center,
Sacramento, Ca lifornia

The most important recent advance in the
medical management of patients with acute and
ch ronic congestive heart failure has been the
application of system ic vasodi lator drugs to reduce ventricu lar afterload, thereby improvin g
low cardi ac output and decreasing increased
venous pressure. Although such drugs have
been employed fo r several years to treat essenti al hypertension, hypertensive heart failure ,
acute hypertensive crises , and angina pectoris ,
only in the past five years has their use become
wid ely popular in the therapy of normotensive
heart failure. 1 While it can be reasoned th at the
vasodilator approach is a log ical therapeutic extension of fundamenta l determinants regulating
cardiac funct ion known for many years, it is
nevertheless intriguing that consideration has
been delayed until the present time of suc h a
useful concept as afterl oad reduction th erapy in
heart failure.

Regulation of Cardiac Function
Th e intact heart is normally govern ed by th e
intimate integration of four prin cipal determinants regulating stroke volume and cardi ac ou tput (Fig 1 ): 1) preload (ventricular end-d iastolic
volume} , 2) contractility (variable force of ventricul ar contraction independent of load ing}, 3)
Supported in part by Resea rch Prog ram Project Grant
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aft erlo ad (ventricular systo li c tension during
ejection} , and 4) heart rate. 2 Th e terms " cardi ac
function " and " ventri c ul ar performance " are
used in the general sense to refer to the combined action of these four determinants of cardiac output, and not necessarily to the singl e
determinant of cont ract ilit y. The disturbed
mec han isms operative in all types of clinical
heart disease can be eva luated and accu rately
measured within the framework of isolated or
composite disorders of these fou r maior determinants of cardi ac performance 3 Besides affording a better understanding of the manner in
whi ch va ri ous types of heart disease lead to disturbed pump performance , appreciation of th e
determinants of cardiac function (Fig 1) provides the rationale for an org ani zed approach to
th e integ ration of therapy in the management of
congestive heart failure. 4

Rationale of Afterload Reduction Therapy
Facilitation of ventricular emptyin g lead in g to
increasing lowered stroke volume is th e fundamental objective of therapy for heart failure .
Conventional treatmen t of congestive heart failure has focused primarily on increasing ventri c ul a r strok e vo lum e and ca rdi ac output
through the use of direct pos itive in otrop ic
agen ts and concomitant diuretic therapy. In th e
case of patients with coronary heart disease in
wh om acute and chronic pump failure results
principally from the impairment and loss of myocardial contractile units, an increase in th e inotropic state of th e remaining functioning heart
musc le may insufficiently augment cardi ac per-

formance. Th e powerful inotropic stimulus of
card iotonic agents may also increase overall
myocardial oxygen demand (MV0 2 ), whi ch is
potentially detrimental in acute ischemic heart
disease. In contrast to elevatin g low stroke output by direct inotropic stimul ati on in heart failure, reduci ng impedance to left ventricular ejection by ad ministrati on of systemi c arteriolar
dilator drugs provides a uniqu e th erapeutic
mechanism for th e augmentation of pump perform ance by increasing ventricular emptying ,
whil e also diminishing MV0 2 . 5

Determinants of Ventricular Afterload
As with ventricular filling (preload) , several
factors influence afterl oad and impedance to
left ventricular outflow. The load or tension that
th e left ventricle must develop to e1ect stroke
volum e constitutes ven tri cular afterl oad. Afterload is defined as th e wall tension during left
ventricular ejection 5 Th e two principal determinants of afterload are systolic pressure and
rad ius of the ventricle , accordin g to the Laplace
formula. In turn , systolic pressure is related to
impedance to blood fl ow in the aorta, and the
radius of the ventricu lar chamber is related to
left ventricular volume (preload).
Determinants of Aortic Impedance
Impedance to left ventricular ejecti on is th e
instantaneous relation between the rate of
change in aortic pressure and aorti c fl ow .5 Left
ventricular outflow impedance is governed primarily by two factors 1) th e compliance (relation of pressure to fl ow) in the large arteri es; and
2) th e total peripheral vascular resistance (the
rate of run off from the systemic arteri al tree)
which is determin ed principally by th e radi us or
cross-sectional area of the systemic arteriolar
beds. Of th ese factors reg ulating impedance,
systemic arteri olar resistance is the most important and th e vari able most subject to modification by pharmacologic vasodilation
Determinants of Left Ventricular Energetics
In the setting of impai red ventricular performance, elevation of ou tfl ow impedance results in
declines of the extent and rate of fiber shortening and red uction in the ejection fraction with
the consequen t elevation of left ventri cular filling
pressure (preload) Thus stroke volum e must be
maintained at inc reased energy costs rel ated to
the increase in intramyocardial wall tension (af-

CONTRACT I LITY

t
PRELOAD

_CARDIAC__ AFTERLOAD
OUTPUT
EJECTION TENSION

DIASTOLIC VOLUME

•

HEART RATE
Fig 1 -Representation of th e four principal determin ants of
cardiac output

terload) (Fig 2). ~ In severe pump failure, elevations of impedance and preload (afterload product), which are inherent conseq uences of th e
heart fai lure state , result in the ri se of MV0 2 .
Thi s ri se in MV0 2 leads to poten ti al myocardial
ischem ia and continued impairment of pump
function , causin g greater sympathetic-induced
ri se of peripheral vascu lar resistance with resu ltant in creases in ventricu lar afterl oad and preload. Thus a progressively deleterious cycle adversely affectin g MV0 2 and pump performance
is set in motion by th e operat io n of co mpensatory mechanisms attempting to maintain
cardi oc ircu latory integrity. System ic vasod ilator
therapy, which produces reductions in both impedance and preload , interrupts this harmful
chain of events wh ile augmen ti ng cardiac output , diminishing pulmonary congestion and improving myocardi al energetics .5

Clinical Use of Systemic Vasodilators
Whil e it has been two decades sin ce
Bu rch produced gangl ion ic blockade with the
intravenous vasod ilator, hexamethonium , in the
relief of intractable pulmonary congestion due
to left heart failure 6 and Johnson diminished
acute pulmonary edema by sublingual nitroglycerin in left ventricul ar dysfunction ,1 the expressed purpose of th ose two isolated reports
was clearl y the reduction of increased left ventri cular preload and elevated system ic venous
tone in th e amelioration of backward failure (pulmonary congestion) via peripheral venod ilation
Th at vasodilators might be useful in decreasing
raised peripheral arteri al resistance to diminish

WALL TENSION--IMV?2I-- HEART RATE
CONTRACTILITY
FIG 2 -Representation of th e three major determin ants of
myocardial oxygen consumption (MV0 2 ) lntramyocardial
systolic wa ll tension is left ventricular afterload which is a
product of preload (left ven tricular volume) and impedance
(systolic blood pressure)
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pump outflow im pedance with improvement in
forward fai lure (low cardi ac ou tput) was not appreci ated at that time .
Th e pharm acolog ic approach of vasod ilator therapy for impedance red ucti on was first
empl oyed c lin ica ll y in norm otens ive seve re
heart failure by Majid and assoc iates in 19 71 .8
Thu s, infusion of the alpha-ad renergic block ing
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FIG 4- Ventri cular fun ction curves relatin g ventricular performance (cardiac output) to th e aorti c impedance component (total systemic vasc ular resistance) of ventricular afterl oad Th is relati onship beco mes in c reas in gly stee p
(greater depression of cardiac output) as vent ri cular fun cti on
declines from th e normal curve to the curves 0 1 , 0 2 and 0 3
indica ting progressively grea ter depression of ca rdi ac contractility . As card iac dysfun ction worsens, th e point of ventricular functi on (closed circles) of th e prog ressively failing
ventricle on the spectrum of curves shifts to a higher impedance component of alterl oad .
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agent , phentolamine , in acute myocardi al infarction was observed to result in the decline of
elevated systemic vasc ul ar resistance , accompani ed by the ri se of low cardiac output and th e
fall of elevated pulmonary artery pressure, without substan ti al alterations in systemic arteri al
pressure and heart rate . Th e modern era of afterload red uction gained momentum following
reports of similar hemodynamic benefits
ac hieved by intravenous nitroprusside in ac ute
myocardi al infarction pati ents 9 - 11 Th e vasodil ator concept spread rapidly and has now been
extended to the management of severe chroni c
cardiac dysfunction of various types 5 12 - 18
As to why the id ea of afterload redu cti on
th erapy of heart fa ilure was not recog ni zed
sooner, it seems to me th at thi s delay has been
largely th e result of a lac k of understanding , until rece ntly , of the criti cal relationships between
periph eral circ ul ato ry dynamics and ca rdi ac
performance 19 Furthermore , th e relation of ca rdiac ou tput to peripheral vascu lar activity is dependent upon left ventric ular contractility When
th e heart is normal, cardi ac output is principally
governed by systemic venous tone with th e left
ventricle operating on th e steep ascending limb
of its Frank-Starlin g curve (outflow-preload relati on) (Fig 3 ); aorti c impedance reducti on is of
little importance . In contrast , in the presence of
left ventricular dys functi on, arteri al resistance is
elevated and cardi ac ou tput becomes strongly
dependent on ou tfl ow resistance (Fig 4) Thu s,
the interpl ay between impedance (arterial resistance bed) and preload (venous capac itance
bed) redu ct ions is that preload is more important th an impedance in th e norm al hea rt (cardiac output declines) (Fig 3) , while in the failing
hea rt , impedance red uction predomin ates over
preload dec line (cardiac output ri ses) (Fi g 4)
Whil e profound periph eral art eri al and
venous constri cti on accompani es chronic heart
failure,2 onl y recently has it become appreciated that the heightened adrenergi c activity in
respo nse to lowe red ca rdi ac output , while
seemingly useful in maintaining blood pressure,
may result in a greater level of increased systemic vasc ular resistance th an is required to
sustain arteri al pressure , and thu s thi s refl ex
adaptive mechani sm may actu ally further decrease card iac output (Fig 4) 1 A harmful cyc le
is th ereby provoked in which the heart failure
pati ent reaches a greater depression of hemodynami cs than is really optimal , systemi c vascu-

lar resistance being higher and cardiac output
lower than are salutary . In addition , systemic
venoconstriction may also become excessive in
chron ic heart failure. Consequently, there occurs greater elevation of left ventricular enddiastolic pressure than is required relative to the
lowered card iac output on the depressed and
flattened ventricular function curve characteristic of impaired contractility. Importantly, vasodilator therapy possesses the ability to interrupt
this deleterious sequence of events by partially
counteracting the compensatory sympathetic
reflex mechanism. '

Spectrum of Systemic Vasodilator Drugs
A vari ety of intravenous, oral , sublingual
and cutaneous agents are now readily available
which provide a spectrum of actions which result in the elevation of lowered card iac output
by reducing peripheral vascu lar resistance and /
or decline of increased ventricular end-diastolic
volume (ventricular preload) by lowering venous
tone . These drugs produce disparate modifications of cardi ac function by their differing alterations of preload versus impedance, which are
dependent upon their relative effects on systemic arteriolar resistance and venous capaci~
tance vessels characteristic of each agent (Fig
5) 2 0 In addition, these drugs cause concomitant
reduction in MV0 2 which is of special importance in ischemic heart disease.
Th erefore, modulation of cardiac function
by the vasod ilators is determined by their relative preload and impedance effects (Fig 6).
Thus , the nitrates 15 principally cause venod ilation (decrease elevated left ventricular end-diastol ic pressure); nitroprusside ,2 ' phentolam ine,2 0
and prazosin 2 1 produce balanced arterial and
venous dilation (decrease elevated left ventricular end-diastolic pressure and increase lowered
cardiac output) provided left ventricular filling
pressure is maintained at the upper lim it of normal ' ?; while hydralazine ' 3 predominantly effects
arteriolar dilation (increases lowered cardiac
output). With depressed cardiac output plus
highly elevated left ventricular end-d iastolic
pressu re and elevated peripheral vascular resistance , nitrates 'b also ach ieve some increase of
lowered card iac output by markedly reducing
increased peripheral vascular resistance. Combined nitroprusside and dopamine 22 or dobutamine synergistically increase low cardiac output
and decrease raised left ventricular end-dias-
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FIG 5-Diagram of the spectrum of actions of systemic
vasodilators on the peripheral arterial tree and systemic
venous bed. CO = cardiac output ; EDP = left ventricular
end-diastolic pr~ssure ; LVEDV = left ventricular end-diastolic volume; MV0 2 = myocardial oxygen consumption; IV
= intravenous; SL = sublingual ; H = hydralazine.

N

:::!:

'c:
E
' 2 .50
;::::!.
0

u

V>

0"'

>-

Cl.

"'>-

</)

0

u
~

'.3

lo:;---------1:12~-----i~~~~~~
CONGESTION

LVEDP(mm Hg)
FIG 6 -Relationship between card iac output (CO) and left
ven tricular end-diastolic pressure (LVEDP) in a normal subject (left curve) and a patient with congestive heart fa ilure
(CHF) (right curve) Point A indicates the point of operation
of the dysfunctioning left ventricle in CHF. The intermediate
curve ( 1) is the improved relation between CO and LVEDP
after th e administration of digitalis (Point E), nitroprusside
(NP) to above LVEDP of 12 mm Hg (Point B), and NP to below LVE DP of 12 mm Hg (Point C) with the addition of dextran (Point B). Prazosin and combined hydralazine-nitrate
therapy are the same as NP from Point A to Poi nt B. The enhanced CO and reduced LVEDP following the administration of phentolamine (PT) are shown by Point F. Hydralazine
therapy can be represented from Point A to Point E. It is instructive that the improvements from Point A on the lowest
ventricular function curve to Point B on the intermediate
function curve (1) after NP administration and to Point F after PT was given are not th e result of increased contractility;
rather, they are due to the enhanced relation between CO
and LVEDP that the reduction of impedance to left ventricular ejection NP and PT allow. Point D on the CHF curve is
the LVEDP after diuretic or nitrate therapy. The intermediate
curve (2) demonstrates the improvement in CO and decrease of LVEDP achieved with combined NP and dopamine therapy (Point G) The horizon tal broken line indicates
the lower limit of normal for CO and the vertical broken line
indicates the upper limit of normal of LVEDP. Congestion =
pulmonary congestion.
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tolic pressure Mechanical coun terpu lsation
aid s nitroprussid e in acute myocardial infarction. The 30-minute venodilator action of
sublingual nitroglycerin ?3 ? 4 is extended by 4 to
6 hours by cu taneous nitroglycerin ointment, 20
oral isosorbide dinitrate, 10 oral pentaerythritol
tetranitrate, ?6 and by sustained-release nitroglycerin capsu les. ?1 Ambu latory oral vasodilator
therapy is provided by long -acti ng nitrates' 0 (relieve pulmonary congestion) ; hydralazine ' 3 (improves fatigue) ; and prazosin alone, ' 5 ·? 8 combined nitrate-hydralazine, ?9 and comb in ed
prazosin-hydralazine" (improve both dyspnea
and fatigue).

Conclusions and Future Directions
Since activi ty of the renin-angiotensin system is increased in cardi ac dysfunction ,2 ang iotension II contributes in part to the increase of
total peripheral vascular resistance characteristic of the heart fa ilure state. Furthermore , this
renin mechanism is st imul ated in most instances of chron ic systemic vasod il ator th erapy
which attenuates systemic arteri olod ilation produced by such treatment. Because recent evidence has been provided that admin istration of
angiotensin-converting enzyme inhibitor in patients with heart fa ilure resu lts in dilation of the
peripheral arteri al bed with an increase in cardiac output and decrease in left ven tri cu lar filling pressure , considerable attent ion is now
being focused on the eff icacy of oral and intravenous convertin g enzyme inhibitors alone and
in combinati on with conventional system ic vasodilators in c li nical heart failure. 30 In add iti on , the
vasodilator properties of the prostaglandins are
also under evaluation in heart failure th erapy .
The initial adm inistration of the vasodilators to congestive heart failure patients is usually accompanied by a favorable diuresis. However , with prolonged use of the agents, body
fluid accumu lation often takes place, requi rin g
greater dosage of concom itant diuretics. Whil e
oral furosemide is generally useful in this respect , the administration of spironolactone has
been particularly beneficial in effecting diuresis,3 ' probably caused by vasod ilator-stimulation of the renin axis , resulting in increased aldosterone secretion.
With the prolonged use of each of th e oral
vasodilators in the ambu latory treatment of severe congestive heart failure , tolerance to the
agents may develop in some individuals after
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several months. In the case of prazosin, tolerance can occur in approximately one third of
patients after six months of effective therapy 32
This tolerance is surmountable with a return of
prazosin effi cacy by increasing the dose of the
drug, or by the brief discontinuation of the agent
for a few weeks , or by switching for a short peri od to another vasodilator regimen suc h as
trimazosin 33 or comb in ed nitrate-hydralazine
Not a single instance of tachyphylaxis with repeated prazosin adm inistration has been observed in ove r 1 50 heart failure patients to
whom the agent has been given for either investigational or therapeutic purposes at ou r inst itution . The few reports of appa ren t prazosin
tachyphylaxsis can each be read ily attributed to
fa ulty study design and/or in correct interpretation suc h as those by Chatterjee ,34 Packer
et al,34 and Elkayam et al. 36 In contrast , the
chron ic use of hydralazin e in heart fa ilure, besides possible tolerance and the occasional
side effects of the lupus erythematosus syndrome and peripheral neuropathy, may cause
hydralaz in e- indu ced tachycardia , a frequent
and seri ous comp lication ,31 lead ing to potentially lethal dysrhythmias , angina pectoris, and
left ventricular pump deterioration.
Th e most important question as yet unanswered is the effectiveness of vasodilator therapy in ac ute and chron ic refractory heart failure
and in reducing comp li cations and mortality. Although some prelimin ary stud ies have been encouraging , th e definitive answers have not yet
been established If myocardial ischem ia plays
an important role in essential hypertension, cardiomyopathies and chron ic coronary heart disease, then the in creased ventricular filling pressures in these cond itions probably con tribute to
sustained subendocard ial ischemia with resu ltant progression of cardi ac dysfunction ' Provided this mechanism is operative , then reduction of increased filling pressure by vasodi lators
should improve subendocardi al perfusion and
thereby diminish morbidity and extend longevity
It is rema rk ab le how quickly system ic
vasodilator therapy has become established as
an important new medical treatment for both
acu te and chron ic heart failure. ' 9 Perhaps no
other recent therapeutic concept in cardi ovascular medicine has been so rapidl y translated
into practical clinical management as that of reducing left ventricular afterload by means of

vasodilator drugs. In our thinking about the
management of congestive heart failure, it is apparent that a change of focus has occurred
from emphasis on contractility prevalent in the
past decade to innovative considerations of cardiac unloading by agents that primarily relax
vascular smooth muscle without direct actions
on the heart. ' In consort, reexamination of the
proper role of the digitalis glycosides is taking
place.
Some clinicians maintain that the vasodilators are important as adjuncts in severe heart
failure for use when traditional means are inadequate , to be added only in combination with
digitalis and diuretics; others already view the
vasodilators as equal or even better alternatives
than the conventional agents. In the difficult circumstance of refractory acute or chronic heart
failure , the combination 'of vasodilators and
powerful cardiotonics such as dopamine (Fig 6)
or dobutamine in hospital situations, ~ 2 and digitalis38 or promising new oral positive inotropics
on the horizon in outpatient settings,' provide
the most potent pharmacologic augmentation of
pump function possible. It is probable in the future that as more experience is gained with the
vasodilators and as newer agents become available , the systemic vasodilators will be utilized as
frequently as digitalis in the standard treatment
of congestive heart failure .
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Medical Management of Angina
ANDREA HASTILLO, M.D.
Assistant Professor of Medicine, Division of Cardiology, and Director, Coronary Intensive Care Unit,
Medical College of Virginia, Health Sciences Division of Virginia Commonwealth University,
Richmond, Virginia

Evaluation of medical therapy of angina
pectoris can be approached in many ways, but
the objectives remain the same: (1) to relieve
the acute attack of angina pectoris, (2) to prevent its recurrence, (3) to allow the patient to
lead a normal lifestyle or, at least, one that is
acceptable to him or her, and (4) to prevent
myocardial infarction.
Major problems are incu rred when one attempts to evaluate the natural history of angina
pectoris with the effects of various treatments.
Ang ina pectoris is a subjective complaint and
therefore the response to therapy is also subjective. As angina frequently waxes and wanes,
improvement of the patient 's condition does not
necessarily indicate a direct correlation with
treatment , nor does the fact that a patient has
angiographically proven coronary artery disease
and chest pain mean that the coronary lesion is
causing the patient's complaint Furthermore,
many patients treated for angina pectoris who
were later catheterized demonstrated that, despite th e fact th at they had c lassical angina, upwards of 1 0% to 20% of them had insignificant
coronary artery disease. 1
Thus th ere are problems in defining the
criteria by which to judge the patient's response
to medical therapy Electrocardiograms as well
as exerc ise stress testing may show false-positive as well as false-negative patterns. Despite
the fact that not all ang iographically demonstrated lesions cause symptoms, coronary angiography remains the best method by whic h to
judge the etiology of th e patient 's complaint. In
serving as the standard by whic h to define the

Correspondence and reprint requests to Dr. Andrea
Hastillo, Box 83, Medical College of Virginia, Richmond , VA
23298.

presence of coronary artery disease it also provides a basis for the determination of the effectiveness of both med ical and surg ica l interventions.
Wh en correlating the natural history of
ang ina pectoris and its treatment to this standard , one should remember that there are different types of angina Basically , patients demonstrate either simple stable angina or unstable
angina-the latter often being termed ''preinfarction angina" or intermediate syndrome .
After reviewing a number of c linical studies, it
becomes apparent that different investigators
have different definitions of the forms of the
ang ina they describe and hence these studies
are not always comparable . The prognosis of
angina varies with the form of angina being considered. In addition , when the true natural history of angina pectoris cou ld have been studied-t h at is , befo re medi ca l or su rgi cal
intervention was possible-arteri ography was
not available. Al l of these factors have prec luded the exact determination of the effectiveness of medical therapy based on the true natural history of angina pectoris. At the present
time , there is no means by which such a study
cou ld be done. Despite all the problems and
lack of exactitude, one can evaluate, to some
extent, how modern medical th erapy may or
may not help the patient reach the therapeutic
goals outlined above.
In approaching the medical management
of angina, one must be aware that not all angina
is the result primarily of coronary artery disease.
As mentioned earlier, there are other causes of
angina suc h as arrhythmias, severe anemias ,
aortic valve disease , hypertensive cardiovascular disease, and idiopathic hypertrophic subvalvular aortic stenosis which need to be ex-
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eluded or , if included, to be treated. In many
instances therapy (which may include surgery)
aimed at these particular abnormalities may alleviate the patient's angina and make the use of
specific antianginal drugs unnecessary.
The physician should first try to remove
any recognized cause of the angina. The next
step should be an attempt to change the patient 's lifestyle without turning the individual into
a cardiac cripple. The physician should advise
the patient to stop smoking , avoid situations
which might precipitate angina, avoid extreme
environmental hazards , lose weight if necessary , and switch to an appropriate diet to decrease, or possibly reverse the progression of
the atherosclerotic process. Participation in
physician-approved exercise programs may allow the patient to maintain an acceptable lifestyle with a minimum of pain. If the patient is unhappy with the changes in lifestyle or if the
angina persists , the physician must employ additional medical (nitroglycerin may have already
been prescribed) or surgical therapy .
To understand why certain drugs are used
for the relief of angina, one needs to understand
the pathophysiology of ischemia (Fig 1). An individual develops angina or ischemic pain (which
may be manifested by sudden death, angina
pectoris , myocardial infarction , or the intermediate syndrome) when the myocardial oxygen demand exceeds the myocardial oxygen
supply. Basically , medical therapy attempts to
decrease oxygen demand whereas surgical
therapy attempts to improve oxygen supply.
Medical therapy for noncoronary-arterydisease-i nd uced angina pectoris may also
involve changes in the myocardial oxygendemand. For instance, treatment of hypertension reduces intramyocardial tension and
thus decreases oxygen demand. Treatment
with digitalis of heart failure associated with
angina may decrease angina by lowering both
the ventricular volume and the heart rate, and
this , too, reduces oxygen demand; also, by
lowering the left ventricular end-diastolic pressure , coronary vascular resistance is theoretically decreased and the subendocardial oxygen
supply improved. Although digitalis increases
the contractile state , thus increasing oxygen demand , it is hoped that the abatement in heart
rate and ventricular volume will produce a
greater decrease in oxygen demand , thereby
relieving the angina.
30 /
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Cigarette smoking causes undesirable effects on both oxygen supply and oxygen demand; it increases the heart rate and causes
vasoconstriction , both of which increase oxygen demand , and it also decreases the oxygen
supply by shifting the oxygen hemoglobin dissociation curve so that hemoglobin releases oxygen less readily to the tissues. In addition,
smoking increases the carbon monoxide content of the blood , which is bound by hemoglobin
in preference to oxygen ; this, too, decreases
the oxygen supply.
Treatment with certain drugs which can
reduce or alleviate the angina may be indicated.
Specific antianginal drugs include nitroglycerin ,
isosorbide dinitrate , topical nitroglycerin , propranolol and metoprolol .
The various nitrates decrease angina by
causing peripheral venous pooling, thus lowering the intraventricular volume which lessens
oxygen requirements. lntraventricular pressure
may also abate , thereby decreasing coronary
vascular resistance and theoretically improving
subendocardial blood flow. Nitrates may also
lower arterial blood pressure and , as a result,
effect a decrease in impedance to blood flow;
hence, less intraventricular tension will be necessary for blood to be ejected. Problems occasionally arise if a decrease in blood pressure
caused by nitrates produces reflex tachycardia
which in turn causes an increase in the contractile state of the myocardium. Both the increased heart rate and the increased contractility will increase oxygen demand and may
cause angina Furthermore, marked hypotension may develop with the administration of sublingual nitroglycerin which may decrease oxygen supply. However , these problems are
infrequent.
The broad beta-blocker, propranolol , and
the more specific beta-one-blocker, metoprolol,
both decrease oxygen demand 2 by decreasing
the heart rate, the force of myocardial contractility, and the systolic blood pressure . The
theoretical problems of beta-blockers causing
increased ventricular volume which in turn increases oxygen demand and left ventricular
end-diastolic pressure , thus producing increasing coronary resistance and decreasing oxygen
supply , is usually not of clinical significance.
Contraindications for the use of these drugs,
however, are very important. If the patient's
heart rate prior to institution of therapy is 45 or
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50, beta-blockers should not be used or else
used with extreme caution. Insulin-dependent
diabetics who are poorly controlled or who are
unreliable, in general, are not candidates for
beta-blocking drugs. Propranolol should not be
used on pati ents with severe bronchospastic
disease. Metoprolol, being a more specifi c
beta-one-blocker, th eoretically should not cause
as many problems as propranolol, especially
with brochospastic disease; however, it may be
desirable to have these patients on a beta-one
agonist prior to the instituti on of metoprolol.
Though the dose of these vari ous antianginal drugs will vary from individual to individual, a few broad guidelines can be set (Fig 2)
Nitroglycerin is usually the first anti-anginal drug
utilized. Sublingual nitroglycerin should be begun in the lowest dose possible and the first
dose should be given in th e physician's office
while the patient is seated to observe any untoward reactions. Some patients complain of severe headaches and a few may be intolerant of
the drug for this reason. The dose of nitroglycerin should be increased as necessary to
achieve control of th e patient's angina Sublingual nitroglycerin is not solely used for acute
anginal attacks but may also be given prophylactically to patients wh o routinely develop angina with certain situations such as climbing or
engaging in anxiety-producing confrontations.
If angina is frequent, if the patient cannot
tolerate the nitroglycerin or if it is advisable to
avoid using prophylactic nitroglyceri n, then either th e long-acti ng nitrates or propranolol
should be used . Neither the long-acting nitrates
nor propranolol are effective in termi nating the
acute anginal attack; lsordil®'s effect lasts
longer th an th e 1 5-minute changes induced by
nitroglycerin and is often better tolerated by the

patient. However, the duration of lsordil®'s action is variable, and is partially determined by
th e route of administration. Sublingual lsordil®
has a shorter onset of action than the oral form ,
but its effect lasts only 3 to 4 hours whereas
oral lsordil® may be given at 4- to 6-hour intervals . Topical nitroglycerin action lasts for from 4
to 6 hours.
The dose of sublingual lsordil® may vary ·
from 2. 5 mg up to 2 0 mg every 3 to 4 hours,
depending on the patient 's response. If one
uses oral lsordi l®, it is important to realize that
hig her dosages must be used compared to subli ngual lsordil® to produce the same hemodynamic effects; however, the use of oral lsordi l® may be preferred, as it is often better
tolerated by the patient. Though one often starts
with at least 1 0 mg of oral lsordil® every 6
hours, usually at least 2 0 mg every 6 hours is
necessary to achieve improvement. The dosage
of topical nitrog lycerin, like lsordil®, must be titrated by the patient's response. Its advantage is
that a single evening application may prevent
nocturn al angina and permit th e patient to sleep
through the night ; a major disadvantage is that ,
as a paste, it may be aesthetically unpleasing .
Topical nitroglycerin is usually applied in terms
of inches or fractions of an inch and its efficacy
is partially dependent upon the site of application- better absorption obtained when it is
applied above the waist -and the area over
wh ich the paste is applied- the greater the
area, the better the absorption
All nitrates have the potential problem of
decreasing blood pressure and causing reflex
tachycardia. Patients can usually tolerate headache, although aspirin or acetominophen may
have to be added to the regimen.
Propranolol is an effective drug for treatHASTILLO MEDICAL MANAGEMENT OF ANGINA /
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UNDESIRABLE EFFECTS
Nitroglycerin

SL, PRN

Isordil, SL

2.5 - 10 mg. q4h

Isordil, PO

20

- 40 mg. q4-6h

Topical
Nitroglycerin

1/2 - 2" q4-6h

Propranolol

40 - 80 mg. q6h

Tachycardia
Hypotension
Headache

Bradycardia
Bronchoconstriction
Congestive Heart Failure
Rebound Angina
Block Hypoglycemic Symptoms

Fig 2--Commonly used anti-anginal drugs.

ing angina and the best results appear to occur
in patients who have either an elevated blood
pressure or an increased heart rate prior to institution of the drug. In treating angina, one usually prescribes propranolol every 6 hours and
the total daily dose is at least 1 60 mg . The drug
is begun at a lower dose of 1 0 to 20 mg every 6
hours and increased every 2 to 3 days, depending on the patient 's response in terms of blood
pressure , heart rate and symptoms. One should
carefully evaluate the patient for the appearance of peripheral edema, rales, weight gain or
other evidence of heart failure . The end point
for increasing the propranolol varies: precipitation of congestive heart failure, alleviation of
symptoms, or a decrease in heart rate to less
than 50 beats per minute. In some patients, one
may have to stop the drug because of bronchospasm.
Metoprolol was recently introduced in the
United States but has been used in Europe for a
long time. It is quite similar to propranolol but
has less effect on beta-two receptors It is therefore preferable for patients with lung disease.
Otherwise , the many side effects are similar to
those of propranolol. One must remember that
both propranolol and metoprolol are associated
with rebound angina if the drug is rapidly withdrawn from patients who have responded .
Equipotent dosages of propranolol and metoprolol are about 40 mg of propranolol and 50
mg metoprolol and appear to produce the same
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decrease in heart rate , reduction of angina pectoris, reduction of nitroglycerin consumption
and improvement in exercise tolerance testing .
In European studies, propranolol and metoprolol were given every eight hours, but in the
United States, administration of propranolol
every six hours is more common.
Specific studies with lsord il®, in which the
drug was continued for up to 5 to 6 months,
have shown sustained symptomatic relief in
terms of the decreased frequency of anginal attacks, the number of nitroglycerin tablets used
by the patient , and improved exercise tolerance. Other studies have shown that continued
administration of lsordil® does not interfere with
the patient 's usual response to sublingual nitroglycerin: it does not blunt hemodynamic effects
induced by nitroglycerin or the relief of angina
Similar results have been obtained with longterm studies of nitroglycerin ointment. One can
therefore conclude that there is good evidence
that lsordil® and topical nitroglycerin do cause
improvement in the patient's symptoms and
functional status both subjectively and objectively , possibly for several months. However,
none of these studies answer the question "' will
they prevent myocardial infarction and sudden
death?"
Propranolol and metoprolol have been
studied in a similar manner. In 1969, 3 patients
clinically defined as having angina pectoris
were further subdivided into those having coro-

nary artery disease as judged by coronary arteriography (50% occlusion of at least one coronary artery) or a demonstrated transmural
infarction , and a second group of patients with
clinical angina but negative coronary arteriograms. Successful response to propranolol was
defined by at least a 50% decrease in incidence of angina, a 50% decrease in the number of nitroglycerin tablets used , or loss of one
or more provoking factors of angina . Only 23%
of patients with clinical angina but without
proven coronary artery disease responded to
the drug; the patients with proven coronary artery disease responded 86% of the time. Thus ,
without employing coronary arteriography one
could have concluded that propranolol was less
successful in the treatment of angina pectoris
than it really is. This study showed that the dose
of propranolol required for a favorable response
was 1 60 to 2 40 mg a day and that the response to the drug did not correlate with the
number of vessels involved or the severity of the
patient 's pretreatment angina.
In 1976 another study4 attempted to show
that the patient 's response to propranolol appeared to affect mortality. Despite some loopholes the study did clearly indicate that patients
who failed to respond to medical management
appeared to have a worse prognosis than the
responders; these nonresponders are therefore
the patients who are usually referred for su rgery.
Most studies conclude th at high doses of
propranolol clearly decrease the incidence of
angina and allow the patients to lead more normal lives. Other evidence has shown that exerc ise to lera nce a lso improves , although if
metoprolol and propranolol are used , it is often
not angina that curtails the patient's activity but
frequently a fatigue-like synd rome; some studies have shown th at if the patient is maintained
on a combination of propranolol and isosorbide
dinitrate, exercise tolerance improves even

more. It would seem logical that as these two
drugs affect different determinants of oxygen
demand , a combi nation of th e two might be
more effective than either one used singly
In summary , one can clearly state that the
medical therapy of angina pectoris is better than
no th erapy at all and that some patients clearly
do obtain subjecti ve as well as objective improvement. However, one still cannot determine
whether or not there is clear improvement utilizing med ical therapy in terms of mortality relative
to the natural history of the disease. There are
also limitations to the use of th e drugs and there
are c learly failures ; these drugs do not halt progression of th e underlying atherosclerotic process and therefore do not cure. The choice between medical or su rgical therapy depends on
many factors which are often defined by ang iography, determined by th e failure of whatever
the physician believes to be maximu m medical
therapy , and commonly influenced by the local
surgeon 's skills. The patient as well as the physician has a profound influence on whether
medical or surgical therapy is ultimately used .
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The Management of Patients with Premature
Ventricular Contractions
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Premature ventricular contractions (PVCs)
occur frequently in patients with virtually all
types of cardiac disease and in persons without
evidence of cardiac disease. Since PVCs and
advanced grades of PVCs are known to be predictors for ventricular fibrillation, increased mortality , and sudden death in certain clinical settings, the management of patients with PVCs is
frequently based on the clinical setting in which
they occur. For the purpose of this talk we will
discuss the treatment of PVCs in the following
three instances: acute myocardial infarction in
the coronary ca re unit , post-myocardial infarction patients , and persons without any evidence of organic heart disease.

Acute Myocardial Infarction
Almost all patients with acute myocardial
infarction have PVCs during the first few days .
The frequency of PVCs is greatest in the first
hours after infarction and decreases gradually
and progressively during the next several hours
and days In acu te myocardial infarction, Lown
and co-workers 1 described certain types of
PVCs that commonly preceded ventricular fibrillation. They applied the term "serious ventricular arrhythmias' ' to the following types of PVCs:
(1) occurrence at a rate of five or more per
minute , (2) " R on T" phenomenon, (3) multiform PVCs , (4) paired PVCs, and (5) ventricular
tachycardia. When observed on routine monitoring , these premonitory ventricular arrhythCorrespondence and reprint requests to Dr. Donald
W. Romhilt, Box 51 , Medical College of Virginia, Richmond,
VA 23298 .
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mias were treated with lidocaine, and Lown and
associates reported less than a 2% incidence of
primary ca rdia c arrest in 300 patients with
acute myocardial infarction. 2 The detection of
serious ventricular arrhythmias from the cardiac
monitor followed by suppression with antiarrhythmic drugs is the approach in many coronary care units today
There are two problems with this approach. First, the serious ventricular arrhythmias
appear to be neither very sensitive nor very specific for the subsequent development of ventricular fibrillation. El-Sherif and associates 3
found that only 11 (58%) of 1 9 patients with an
acute myocardi al infarction who developed ventricular fibrill ation had premonitory arrhythmias.
In the 1 7 patients where ventricular fibrillation
was preceded by a single PVC , 1 0 had early
PVCs or " R on T" phenomenon. Of the 430
patients without ventricular fibrillation in this series , 236 (55%) had premonitory ventricular arrhythmias and 1 94 (45%) did not. A second
study 4 reported similar findings
The second problem is the adequacy of
the detection system for arrhythmias as it is routinely employed in the coronary care unit. We
compared the recognition of arrhythmias in 31
patients with acute myocardial infarction by the
nurses and by rate-alarm signals in the coronary
care unit with a continuous five-day tape recording that was subsequently processed through
an automated Hewlett-Packard arrhythmia detection system. The Hewlett-Packard system
printed out all arrhythmias for verification and
quantification by the investigators.5 The observation of conventional monitors by coronary

care unit personnel in conjunction with ratealarm systems resulted in an inadequate detection rate of PVCs and serious ventricular arrhythmias compared to the subsequent analysis
of the tape recording (Table). In addition, there
was a considerable time delay between the initial occurrence of PVCs and serious ventricular
arrhythmias on the tape and their recognition by
coronary care unit personnel Arrhythmia recognition in coronary care units has improved and
computer systems are available which can be
used on line to improve the detection rate for
PVCs; however, most coronary care units continue to rely on trained personnel for arrhythmia
recognition.
Since there is such a high incidence of
PVCs in patients with acute myocardial infarction , the prophylactic administration of antiarrhythmic drugs has been evaluated extens ively. Initially quinidine , 6 procainamide, 7
lidocaine, 8 and phenytoin 9 were reported to reduce significantly PVCs and serious ventricular
arrhythmias , without reducing mortality The patients in these studies were always a good-risk
population with a low mortality in the control
groups. In addition , when arrhythmias were recognized in the control groups, they were
treated. More recently, Lie and co-workers 1 0 in
a double-blind randomized study demonstrated
that lidocaine given prophylactically as an initial
1 00 mg bolus followed by an infusion rate of
three mg/min significantly decreased the incidence of primary ventricular fibrillation , but
mortality was not effected since all but one patient with ventricular fibrillation was resuscitated.
The frequency of side effects at this infusion
rate was 1 5% and was higher in the 60- to 70year age group than in patients below the age
of 60.
Since the PVC predictors for ventricular
fibrillation are less reliable than indicated in initial reports, and PVC detection by conventional

monitoring in the coronary care unit is not optimal, there is evidence available to recommend
the prophylactic administration of lidocaine to
patients during the first 48 to 72 hours of an
acute myocardial infarction for the prevention of
primary ventricular fibrillation. Patients with evidence of heart block, cardiogenic shock, severe congestive heart failure , and sinus bradycardia (below the rate of 50) probably should be
excluded from this recommendation. Since patients above the age of 70 apparently have a
low incidence of primary ventricular fibrillation in
the coronary care unit and a higher incidence of
adverse reactions to lidocaine , they also should
probably be excluded from this recommendation.
The dosage of intravenous lidocaine used
for prophylaxis is important. When a loading
dose of 50 to 1 00 mg followed by a 2 mg/min
infusion rate is used , there is an initial period of
six to seven hours when plasma levels are suboptimal. 11 In an effort to avoid 't,/lis dip in plasma
levels it is necessary to give about 200 mg of
lidocaine in the first 20 minutes. 1 2 There are
several ways to give this loading dose: (1) 1 00
mg given twice at ten-minute intervals; (2) 50
mg given four times at five-minute intervals; (3)
infusion of 20 mg / min for ten minutes; and (4)
1 00 mg bolus followed by infusion of 6 to 7
mg / min for 1 5 minutes. I prefer the last method
followed by the continuous administration at an
infusion rate of 2 to 4 mg / min , preferably 3
mg / min In patients with shock , congestive
heart failure , or hepatocellular disease, the
loading dose and infusion rates should be decreased by about 50%. This may also apply to
patients over the age of 7 0 . If PVCs occur , the
plasma concentration of lidoca ine can be raised
rapidly with a 25 to 50 mg bolu s and an increase in the infusion rate. There is some evidence that the plasma half-life of lidocaine increases by a factor of about two after 24 hours

TABLE
Arrhythmia Recognition in Acute Infarction
(3 1 Pati ents)

Premature Ventricular Contrac ti ons
Seri ous Ventricular Arrhyth mias
Pre mature Atrial Contrac ti ons
Ventric ular Fibrillation, Atri al
Fibrillati on, Asystole, Complete
Heart Bloc k, Jun ct ional Tachyca rdi a

AU TOMATED

TIM E D ELAY

CONVE NTIONAL

D ETECTION

IN R ECOG NITION

M ONI TOR

SY STE M

(H OURS)

64 .5 %
16%
4 5.2 %

100%
9 3 5%
96 .8%

18
10

Identical

Identical
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in patients with acute myocardial infarction, thus
the infusion rate may have to be decreased at
this time. 1 3

Post-Myocardial Infarction
In patients with a previous myocardial infarcti on many stu dies have reported an increased mortality and /or an increased frequency of sudden death in patients with PVCs
or advanced grades of PVCs. 14 - 1 8 Although
there is some variabliity in the reported studies,
the increased mortality appears to be true for
th e prese nce of PV Cs o n a routin e electrocardiogram as in the Coronary Drug Project , 14 and for an increased frequency of PVCs
(>1 0 per hour or > 20 per hour) or advanced
grades of PVCs or both during monitoring studies. In contrast to these studies, the work of
Moss and co-workers, 18 · 19 has indicated that
PVCs and advanced grades of PVCs have limited use in predi c tin g subsequent ca rdiac
events and a similar study has been reported by
de Soyza and associates. 2 0 It is likely that PVCs
and advanced grades of PVCs will be neither
sensitive nor specific for the prediction of subsequent mortality in post-myocardial infarction
patients similar to the findi ngs in patients with
acute myocardial infarcti on. There may be two
exceptions to this. The first exception may be
those patients with a low-ejection fraction (less
than 4 0%) and advanced grades of PVCs who
have an increased incidence of sudden death
compared to patients with a low-ejection fraction without advanced grades of PVCs. 2 1 The
second exception may be those patients who
develop ventricular arrhythmias with low-level
exercise tests to a heart rate of 1 3 0 beats per
minute o r symptoms at three wee ks postinfarction. 22
There are three controlled clinical trials
that have been carried out in Europe, evaluating
the prophylactic administration of beta adrenergic-blocking drugs in postinfarction patients
The fi rst trial, in Sweden, using alprenolol in
23 0 patients demonstrated a significant reduction in sudden death , but not in total mortality or
recurrent infarction 23 The second study , also in
Sweden and also using alprenolol, reported a
significant reduction in sudden death and recurrent infarction but not in total mortality.2 4 A large
rriulticenter trial in England with practolol demonstrated a significant reduction in cardiac
death and sudden death, particularly after ante-
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rior infarctions. 25 In thi s trial the rate of recurrent
infarction was reduced but was not statistically
significant. The trial had to be terminated because of the ocular complications associated
with long-term practolol administration. Since
the incidence of recurrent infarction was shown
to be reduced , the mechanism of the beneficial
effect of beta adrenergiccblocking drugs may
not be entirely related to their antiarrhythmic
properties. In June 1978 a large multicenter
trial was started in the United States, using propranolol in post-infarction pati ents, and the
Medical College of Virginia is one of the clinical
centers.
It is possible that oral antiarrhythmic drugs
(quinidine, procainamide, disopyramide, phenytoin , or propranolol) on a long-term basis may
be beneficial in postinfarction patients , but the
results of additional clinical trials with drugs
available in the United States are needed . At the
present time postinfarction patients with frequent or advanced grades of PVCs may benefit
from antiarrhythmic drugs, partic:;ularly when the
PVCs are associated with a low-ejection fraction , angina pectori s, or a positive exercise test.
It is essential that patients have a baseline monitoring or exerc ise study (whichever demonstrated the PVCs) prior to therapy and again after institution of therapy in conj unction with
blood levels of the drug , when available, to evaluate the effectiveness of the antiarrhythmic
therapy. It also should be remembered th at we
do not really have a good oral antiarrhythmic
drug approved for use in the United States.

Without Organic Heart Disease
The significance of PVCs in persons without evidence of organic heart disease is less
clear and can be a difficult probl.em with respect
to treatment. Hinkle and co-workers reported
that 6 2% of middle-aged American men had
PVCs during a six-hour recording .2 6 The presence of PVCs or more than 1 0 PVCs per 1 000
beats correlated with an increased risk of sudden death . In the Tecumseh Study there was a
significant increase in mortality in persons over
the a g e o f 3 0 with PV Cs o n an ele ctrocardi og ram com pared to those with o ut
PVCs. 27 However, in both of these studies there
was also a correlation between PVCs and the
presence of coronary artery disease . Thu s,
PVCs appear to be only a marker for coronary
artery disease in these studies, but are not spe-

cific enough for coronary artery disease to be
useful in individual patients Fifty percent of
male medical stud ents had PVCs during a 24hour period , but on ly 2% had more th an 50
PVCs during the 24 hours. 28 In persons without
organic heart disease PVCs are frequently associ ated with fatigu e, anxiety , or use of coffee, tobacco, tea or alcohol. 2 9 Removal of th ese factors will often decrease or eliminate the PVCs.
In general the use of anti arrh ythmi c drug s
sho uld be avo ided in individu als who have
PVCs without evidence of org anic heart disease.
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